Fulgent Genetics’s Investor Alert: Kaplan Fox Reminds Investors of an Important Deadline
Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) reminds investors that a securities class action case has been brought against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) and that November 21, 2022 is the deadline for seeking appointment as lead plaintiff
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) reminds investors that a securities class action case has been brought against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) and that November 21, 2022 is the deadline for seeking appointment as lead plaintiff.
If you purchased or otherwise acquired Fulgent securities during the period March 22, 2019 and August 4, 2022, inclusive (the “Class Period”) and would like to discuss this case and our investigation, please contact attorney Jeffrey Campisi at (212) 687-1980 or by emailing jcampisi@kaplanfox.com.
If you are a member of the proposed Class, you may move the court no later than November 21, 2022 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On August 4, 2022, after the market closed, Fulgent released its second quarter 2022 financial results which were filed with the U.S. Securities and Exchange Commission on Form 10-Q, disclosing, among other items, that the SEC is conducting an investigation into certain reports for 2018 through the first quarter of 2020. Specifically, the Company advised, in relevant part:
